App-Quantinova.ai

Predictors of long‐term normal histology on protocol allograft biopsies

Jeremy K. Raianavagam - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

NK cells in the ascites of patients with advanced liver cirrhosis are phenotypically distinct from blood and liver NK cells and may be involved in antibacterial defense

Philipp Lutz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

N/A

Acute kidney injury on the transplant waiting list: Effect on post‐liver transplantation renal and patient outcomes

Shuet Fong Neong - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Hepatic encephalopathy

N/A

Stromal Sulfatase‐2 ‐ a critical regulator of hepatocellular carcinoma growth and migration

Marco Y. Zaki - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Lipogranulomas, neutrophils and the progression of NAFLD to NASH and HCC

Joao C. Mauricio - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

Elaszym

Hepatitis B core‐related antigen (HBcrAg) is useful marker in HBV/HDV co‐infection and can help to predict response to pegylated interferon therapy

Ivana Carey - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Interferon

HBsAg and HBcrAg concentrations differ between genotype A1 and A2 HBeAg negative patients with chronic hepatitis B: complexity within sub‐genotypes has implications for newer therapy paradigms

Ivana Carey - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Desogestrel/ethinyl estradiol

Serum HBsAg levels predict the severity of liver fibrosis among HBeAg‐positive patients across all major HBV genotypes and among patients with low ALT levels: results from the SONIC‐B cohort

Milan J. Sonneveld - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Alkaline phosphatase

Do HBsAg concentrations > 4 log10IU/ml represent a risk for mother to child transmission of HBV infection in all chronic hepatitis B patients?

Ivana Carey - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Web‐based education program improves patient education and understanding of chronic Hepatitis B

Enoka Gonsalkorala - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

HBsAg and HBcrAg as predictors of seroconversion in a pan‐genotypic population of hepatitis B e antigen positive patients treated with nucleos(t)ide analogues

Bo Wang - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Risk of hepatitis B virus (HBV) infection and re‐activation after discontinuation of tenofovir and/or lamivudine as part of antiretroviral therapy in a high HBV endemicity setting

ADAM Abdullahi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Lamivudine

The impact of treatment of chronic hepatitis B (CHB) on patient‐reported outcomes (PROs)

Zobair M. Younossi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Chronic Liver Disease

Tenofovir disoproxil fumarate

Preclinical analysis of liver‐targeted, mild mitochondrial protonophores for treatment of non‐alcoholic fatty liver disease and steato‐ hepatitis

Magnus Hansson - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

N/A

Fully human in vitro gut‐liver model of non‐alcoholic steatohepatitis

Tomasz Kostrzewski - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

DE-074

Lipopolysaccharide increases the release of CXCL5 in an ex‐vivo model for human non‐alcoholic fatty liver disease

Olivier Govaere - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Fatty Liver Disease

N/A

The Physiological, Pathological and Molecular Basis of Nonalcoholic Steatohepatitis Associated Cardiomyopathy

Abdul Oseini - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Inhibition of NADPH Oxidase in Phagocytes Improves Hepatic Steatosis, Inflammation and Fibrosis in a Mouse Model of Severe Nonalcoholic Steatohepatitis (NASH)

Lucy M. Golden-Mason - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Single cell characterization of patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) transcription pattern in human liver biopsies of nonalcoholic fatty liver disease

Bynvant Sandhu - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

N/A

Collagen turnover biomarkers distinguish healthy from NAFLD patients and aid identification of patients with evidence of histologically active NASH

Saurabh Gupta - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

N/A

Filters

45280 Abstracts